Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron D Goldberg

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
Leukemia Research|May 15, 2020
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancyChetasi Talati, Aaron D Goldberg, Amanda Przespolewski, et al.
American Journal of Hematology|October 21, 2021
Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasmsAmber C King, Taylor M Weis, Andriy Derkach, et al.
Leukemia & Lymphoma|October 14, 2024
HMA/VEN treatment modifications and associated outcomes in <i>IDH</i>-mutant AMLKuo-Kai Chin, Andriy Derkach, Christopher Famulare, et al.
Leukemia Research|September 15, 2022
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclaxJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Leukemia & Lymphoma|October 26, 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitorsJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Blood|December 9, 2022
Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemiaAmanda Przespolewski, Aaron D Goldberg, Chetasi Talati, et al.
Leukemia Research|June 11, 2020
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I studyAaron D Goldberg, Ehab Atallah, David Rizzieri, et al.
Cancer Immunology Research|May 23, 2019
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L Smith, Sham Mailankody, Mette Staehr, et al.
Blood Advances|December 5, 2020
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data HubWilliam A Wood, Donna S Neuberg, J Colton Thompson, et al.
Cancer|August 7, 2025
Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costsHannah Burton, Leora Boussi, David Nemirovsky, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Leukemia Research|May 15, 2020
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancyChetasi Talati, Aaron D Goldberg, Amanda Przespolewski, et al.
American Journal of Hematology|October 21, 2021
Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasmsAmber C King, Taylor M Weis, Andriy Derkach, et al.
Leukemia & Lymphoma|October 14, 2024
HMA/VEN treatment modifications and associated outcomes in <i>IDH</i>-mutant AMLKuo-Kai Chin, Andriy Derkach, Christopher Famulare, et al.
Leukemia Research|September 15, 2022
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclaxJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Leukemia & Lymphoma|October 26, 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitorsJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Blood|December 9, 2022
Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemiaAmanda Przespolewski, Aaron D Goldberg, Chetasi Talati, et al.
Leukemia Research|June 11, 2020
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I studyAaron D Goldberg, Ehab Atallah, David Rizzieri, et al.
Cancer Immunology Research|May 23, 2019
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L Smith, Sham Mailankody, Mette Staehr, et al.
Blood Advances|December 5, 2020
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data HubWilliam A Wood, Donna S Neuberg, J Colton Thompson, et al.
Cancer|August 7, 2025
Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costsHannah Burton, Leora Boussi, David Nemirovsky, et al.
Pageof 7